87 related articles for article (PubMed ID: 24798623)
21. Factor XIII and Endothelial Dysfunction in Patients with Systemic Sclerosis.
Alesci S; Wahle M; Himsel A; Miesbach W
Hamostaseologie; 2023 Dec; 43(6):411-417. PubMed ID: 37127039
[TBL] [Abstract][Full Text] [Related]
22. Potential biomarkers for vascular damage in Alzheimer's disease: thrombomodulin and von Willebrand factor.
Yavuz BB; Dede DS; Yavuz B; Cankurtaran M; Halil M; Ulger Z; Cankurtaran ES; Aytemir K; Kabakci G; Haznedaroglu IC; Ariogul S
J Nutr Health Aging; 2010 Jun; 14(6):439-41. PubMed ID: 20617285
[TBL] [Abstract][Full Text] [Related]
23. Imbalance of the von Willebrand Factor - ADAMTS-13 axis in patients with retinal vasculopathy with cerebral leukoencephalopathy and systemic manifestations (RVCL-S).
Braune M; Metelmann M; de Fallois J; Pfrepper C; Barrantes-Freer A; Hiller GGR; Unger S; Seelow E; Halbritter J; Pelz JO
Neurol Res Pract; 2024 Jun; 6(1):32. PubMed ID: 38898536
[TBL] [Abstract][Full Text] [Related]
24. Association between gut-derived endotoxins and porto-sinusoidal vascular disorder with portal hypertension.
Gioia S; Carnevale R; Tavano D; Overi D; Ridola L; Nardelli S; Merli M; d'Amati G; Pellicelli A; Cardinale V; Giannelli V; Baiocchini A; Riggio O; Gaudio E; Carpino G
Aliment Pharmacol Ther; 2023 Dec; 58(11-12):1205-1216. PubMed ID: 37728001
[TBL] [Abstract][Full Text] [Related]
25. Von Willebrand Factor Antigen Levels Predict Poor Outcomes in Patients With Stroke and Cancer: Findings From the Multicenter, Prospective, Observational SCAN Study.
Kawano T; Gon Y; Sakaguchi M; Yamagami H; Abe S; Hashimoto H; Ohara N; Takahashi D; Abe Y; Takahashi T; Okazaki S; Todo K; Mochizuki H; Sasaki T;
J Am Heart Assoc; 2024 Feb; 13(3):e032284. PubMed ID: 38240254
[TBL] [Abstract][Full Text] [Related]
26. [Effect of growth hormone supplementation on liver and lung function in patients with hypopituitarism].
Mao JF; Xu HL; Liu ZX; Wang X; Yu BQ; Zhu YY; Ji W; Zhang JY; Nie M; Wu XY
Zhonghua Yi Xue Za Zhi; 2024 Feb; 104(6):450-452. PubMed ID: 38326058
[TBL] [Abstract][Full Text] [Related]
27. Hepatopulmonary syndrome.
Kovvuri HLR; Karyampudi A; A SK
Indian J Gastroenterol; 2023 Jun; 42(3):436-437. PubMed ID: 37142804
[No Abstract] [Full Text] [Related]
28. Von Willebrand Factor Level Indicate Response to β-Blockers in Cirrhosis: Need a Closer Look!
Jindal A
Clin Gastroenterol Hepatol; 2022 Jun; 20(6):e1513-e1514. PubMed ID: 34371165
[No Abstract] [Full Text] [Related]
29. Von Willebrand Factor as a Biomarker for Liver Disease - An Update.
Elhence A; Shalimar
J Clin Exp Hepatol; 2023; 13(6):1047-1060. PubMed ID: 37975050
[TBL] [Abstract][Full Text] [Related]
30. Serum Soluble Vascular Endothelial Growth Factor Receptor 1 as a Potential Biomarker of Hepatopulmonary Syndrome.
Li YJ; Wu XF; Wang DD; Li P; Liang H; Hu XY; Gan JQ; Sun YZ; Li JH; Li J; Shu X; Song AL; Yang CY; Yang ZY; Yu WF; Yang LQ; Wang XB; Belguise K; Xia ZY; Yi B
J Clin Transl Hepatol; 2023 Oct; 11(5):1150-1160. PubMed ID: 37577229
[TBL] [Abstract][Full Text] [Related]
31. Integration of deep learning-based histopathology and transcriptomics reveals key genes associated with fibrogenesis in patients with advanced NASH.
Conway J; Pouryahya M; Gindin Y; Pan DZ; Carrasco-Zevallos OM; Mountain V; Subramanian GM; Montalto MC; Resnick M; Beck AH; Huss RS; Myers RP; Taylor-Weiner A; Wapinski I; Chung C
Cell Rep Med; 2023 Apr; 4(4):101016. PubMed ID: 37075704
[TBL] [Abstract][Full Text] [Related]
32. Hepatopulmonary syndrome.
Raevens S; Boret M; Fallon MB
JHEP Rep; 2022 Sep; 4(9):100527. PubMed ID: 36035361
[TBL] [Abstract][Full Text] [Related]
33. The Role of von Willebrand Factor Antigen in Predicting Survival of Patients with HBV-Related Cirrhosis.
Pan Y; Guo R; Lv Y; Cui D; Xie J
Can J Gastroenterol Hepatol; 2022; 2022():9035971. PubMed ID: 35360443
[TBL] [Abstract][Full Text] [Related]
34. Von Willebrand Factor, Factor VIII, and Other Acute Phase Reactants as Biomarkers of Inflammation and Endothelial Dysfunction in Chronic Graft-Versus-Host Disease.
Lelas A; Greinix HT; Wolff D; Eissner G; Pavletic SZ; Pulanic D
Front Immunol; 2021; 12():676756. PubMed ID: 33995421
[TBL] [Abstract][Full Text] [Related]
35. The Addition of C-Reactive Protein and von Willebrand Factor to Model for End-Stage Liver Disease-Sodium Improves Prediction of Waitlist Mortality.
Starlinger P; Ahn JC; Mullan A; Gyoeri GP; Pereyra D; Alva-Ruiz R; Hackl H; Reiberger T; Trauner M; Santol J; Simbrunner B; Mandorfer M; Berlakovich G; Kamath PS; Heimbach J
Hepatology; 2021 Sep; 74(3):1533-1545. PubMed ID: 33786862
[TBL] [Abstract][Full Text] [Related]
36. Targeting von Willebrand factor in liver diseases: A novel therapeutic strategy?
Groeneveld DJ; Poole LG; Luyendyk JP
J Thromb Haemost; 2021 Jun; 19(6):1390-1408. PubMed ID: 33774926
[TBL] [Abstract][Full Text] [Related]
37. von Willebrand factor as a biomarker of clinically significant portal hypertension and severe portal hypertension: a systematic review and meta-analysis.
Zou Z; Yan X; Li C; Li X; Ma X; Zhang C; Ju S; Tian J; Qi X
BMJ Open; 2019 Aug; 9(8):e025656. PubMed ID: 31473610
[TBL] [Abstract][Full Text] [Related]
38. von Willebrand Factor Antigen Predicts Outcomes in Patients after Liver Resection of Hepatocellular Carcinoma.
Schwarz C; Fitschek F; Mittlböck M; Saukel V; Bota S; Ferlitsch M; Ferlitsch A; Bodingbauer M; Kaczirek K
Gut Liver; 2020 Mar; 14(2):218-224. PubMed ID: 30428508
[TBL] [Abstract][Full Text] [Related]
39. Potential Clinical Targets in Hepatopulmonary Syndrome: Lessons From Experimental Models.
Raevens S; Fallon MB
Hepatology; 2018 Nov; 68(5):2016-2028. PubMed ID: 29729196
[TBL] [Abstract][Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
